Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAP3K14 antisense RNA 1 (MAP3K14-AS1)
- Target
- MAP3K14-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense transcript
01
Overview
MAP3K14 antisense RNA 1 is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the MAP3K14 locus. It does not encode a protein and functions most likely by regulating the expression of the MAP3K14 gene or neighboring genes. Reported methylation changes of MAP3K14-AS1 have been observed in the hippocampus of epilepsy patients, suggesting a role in the regulation of neuroinflammatory and epileptic processes. While MAP3K14-AS1 itself is not a classical therapeutic target like a receptor or enzyme, emerging research proposes lncRNAs—including antisense RNAs like MAP3K14-AS1—as potential drug targets or biomarkers in diseases such as epilepsy and cancer through epigenetic and post-transcriptional mechanisms. Direct drug interactions or mechanisms remain to be specifically elucidated for MAP3K14-AS1 itself.
- Other names
- MAP3K14 antisense RNA 1MAP3K14-AS1
02
Mechanism of action
For other lncRNAs, antagoNATs may upregulate associated protein-coding genes (such as sodium channels in epilepsy) by inhibiting the antisense RNA. Mechanisms for MAP3K14-AS1 specifically remain uncharacterized.
03
Biological functions
Potential epigenetic regulation of gene expressionPossible involvement in neuroinflammatory pathwaysMay participate in the regulation of apoptosis and cell proliferation in neuronal contextsAssociated with modulation of inflammation in neurological disease models
04
Disease associations
Reported involvement or altered methylation in epilepsy and neuropsychiatric disordersPossible regulatory roles in cancer and inflammation (by similarity with other lncRNAs)Possibly implicated in broader neurological diseases due to its function as a lncRNA
05
Safety considerations
As a newly identified regulatory lncRNA, specific safety concerns for direct targeting remain undetermined.General concerns for targeting lncRNAs may include unpredictability of off-target effects due to broad regulatory functions.
06
Interacting drugs
No direct drugs targeting MAP3K14-AS1 are currently described. However, experimental strategies such as antagoNATs (antisense oligonucleotides targeting natural antisense transcripts) have been used for similar lncRNAs, including epilepsy-related lncRNAs.
07
Biomarkers
Altered methylation of MAP3K14-AS1 in brain tissue has been reported as a biomarker in epilepsy patients
Beyond the preview
Go deeper on MAP3K14 antisense RNA 1 (MAP3K14-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAP3K14 antisense RNA 1 (MAP3K14-AS1).